BASEL LIFE 2019

9–12 September 2019

Congress Center Basel
Switzerland

Genome editing (CRISPR/Cas9) in drug discovery

Date

Thursday, 12 September 2019

Chairs

Filip Roudnicky (Roche, Switzerland)
Claas Aiko Meyer (Roche, Switzerland)

Abstract

Genome editing technologies allow engineering parts of the genome by removing, adding or altering sections of the DNA Sequence. Recent discovery of the CRISPR/Cas9 system as a technology for genome editing, enables the simplest, quickest and most versatile way of genome editing. CRISPR/Cas9 technology is quickly developing and has already found many applications as a drug discovery tool and even as a potential new therapeutic agent in cellular and gene therapy. This forum focuses on relevant applications of CRISPR/Cas9 for drug discovery such as identification of novel targets through genetic screens, generation of relevant genetic disease models (human cells or animal models) for validation of drug targets and for mechanistic and safety studies. Importantly, current standard practices and perspectives of genome editing in drug discovery will be presented. Furthermore, the forum will show novel applications and discuss future challenges and potential pitfalls of the technology.

09.00 – 15.50

09.00
Introduction

09.05
Mechanisms of genome editing in human cells
Prof. Jacob Corn (Swiss Federal Institute of Technology, Zurich, CH)

09.35
Enhancing genome editing with engineered CRISPR Nucleases
Prof. Benjamin Kleinstiver (Harvard University, Boston USA)

10.05
Capabilities and caveats of CRISPR-mediated drug modifier screens
Prof. Traver Hart (University of Texas MD Anderson, Houston, USA)

10.30
Break

10.45
Leveraging CRISPR Screening for New Target Discovery
Dr. sc Scott Martin (Genentech Inc., San Francisco, USA)

11.15
A Flexible, Rapid and Demand Driven CRISPR Screening and Validation

Dr. Glynn Martin (Horizon Discovery Ltd., Cambridge, UK)

11.45
Break

12.00
Single and combinatorial CRISPR gene perturbations with 3Cs gRNAs
Dr. Sc Manuel Kaulich (Goethe University, Frankfurt, DE)

12.20
CRISPR single-cell sequencing: toward functional biology in high throughput
Prof. Christoph Bock (Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, AT)

12.40
Genome engineering in T cell
Prof. Lukas Jeker (University of Basel, Basel, CH)

13.00
Lunch break & Industry Symposia

14.30
In vivo genome editing: from disease modeling to screening
Danilo Maddalo (Novartis Institutes for BioMedical Research Basel, Basel, CH

14.50
Novel Automation Platforms for Generating Synthetic sgRNA and CRISPR-Engineered Cells at Scale
Dr. sc Kevin Holden (Synthego Corporation, USA)

15.20
Title to be announced
Dr. Richard Somberg (Promega, Madison, USA)

Room Samarkand

Supporter(s)